Since its establishment three years ago, it has served more than 200 projects for more than 80 pharmaceutical companies worldwide.
It is reported that CRO’s “Bangmai Bio” announced the completion of nearly 50 million US dollars B round of financing, Wei Wei Capital led investment, Junlian Capital, Qiming Venture Capital and Lilly Asia Fund and investment. This round of funds will be used to strengthen the comprehensive capacity and information construction of clinical operations, accelerate the overseas strategic layout, and enhance the internationalization of clinical development and product registration.
In order to improve the global layout and service capabilities, in the middle of this year, the company completed the acquisition of Target Health in the United States.
The public information shows that the A round of financing of the company is completed in 2016, the A round of financing is 55 million yuan, and the investors are Qiming Venture Capital, Ding Ding Pharmaceutical and Tai Rui Investment.
The rapid development of innovative drugs worldwide, the R&D investment of pharmaceutical companies has increased significantly, benefiting the CRO (Clinical Contract Research Organization) industry. The CRO model originated in the United States in the 1970s and 1980s. The US medical payment method entered the reform period, and the market began to pay more attention to the investment in innovation and research and development. In order to improve the efficiency of new drug research and development, this R&D outsourcing model has emerged.
Today, the Chinese market has a huge volume and also has a policy dividend for medical innovation. Therefore, the growth rate of China’s CRO industry is higher than the global level. Many domestic CROs have already completed their listings, or are in a stage of rapid development. Companies worthy of attention include WuXi PharmaTech, Kanglong Huacheng, Ruizhi Chemical, Medicilon, Rundong Medicine, and Boteng.
The company is oriented to the global market and has the ability to declare and synchronize development in China, the United States and Europe. The company offers a wide range of services, from development planning to administrative registration and post-market support. The company’s main business includes expert consultation, pharmaceutical affairs and strategy, early development and clinical pharmacology, clinical science and medical affairs, clinical trial operations, biostatistics, clinical programming, data management, drug safety and alert, quality assurance and clinical auditing. System support, etc.
The office of the company is located in major cities such as Shanghai, Beijing and Wuhan, as well as overseas in New York, Washington, San Francisco and Brussels. There are more than 600 employees worldwide, more than 60% of whom have master’s degree or above. One employee has more than 10 years of work experience.
Dr. Tan Lingshi, founder and CEO of the company, said: “The company has provided high-quality clinical trial services for more than 200 projects of more than 80 domestic and foreign innovative pharmaceutical companies. The internationalization ability and standard of a new generation of clinical CROs. After this round of financing, the company will be able to serve more innovative pharmaceutical companies at home and abroad.”